title: Is acarbose equivalent to tolbutamide as first treatment for newly diagnosed type 2 diabetes in general practice? A randomised controlled trial.
abstract: We performed a double blind randomised controlled trial in general practice to assess equivalence between tolbutamide and acarbose with respect to the effect on mean HbA(1c) in newly diagnosed patients with type 2 diabetes. Secondary objectives were to compare the effects of both treatments on fasting and post-load blood glucose and insulin levels, lipids, and adverse events. Patients were randomised to receive acarbose, titrated step-wise to a maximum of 100mg three times daily (n=48) or tolbutamide, similarly titrated to a maximum of 2000 mg in three doses (n=48). The two treatments were considered equivalent if the two-sided 90% confidence interval (CI) for the difference in mean HbA(1c) levels was within the range -0.4 to 0.4%. Results were analysed on an intention-to-treat, per-protocol and on worst-case basis. Both agents reduced the HbA(1c) percentage and fasting blood glucose levels. The difference in mean decrease of HbA(1c) was 0.6% in favour of tolbutamide (90% CI 0.3, 0.9; 95% CI 0.2, 1.0). A worst-case analysis, assuming no change in HbA(1c) for dropouts, yielded a difference in mean decrease of 0.9% (90% CI 0.6, 1.2) in favour of tolbutamide. The difference in mean decrease of fasting blood glucose was 1.0 mmol/l in favour of tolbutamide (95% CI 0.3, 1.7). There were no significant differences in post-load blood glucose, fasting and post-load insulin levels, or lipids. In the acarbose group significantly more patients (15 versus 3) discontinued therapy because of adverse effects, mostly of gastrointestinal origin. We conclude that the results of this study favour tolbutamide over acarbose as first treatment for patients with newly diagnosed type 2 diabetes.
authors.affiliation: Department of General Practice, University Medical Centre Nijmegen, 229 HAG, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands. f.vandelaar@hag.umcn.nl
authors.forename: Floris A
authors.initials: FA
authors.lastname: van de Laar
authors.forename: Peter L B J
authors.initials: PL
authors.lastname: Lucassen
authors.forename: Jaco
authors.initials: J
authors.lastname: Kemp
authors.forename: Eloy H
authors.initials: EH
authors.lastname: van de Lisdonk
authors.forename: Chris
authors.initials: C
authors.lastname: van Weel
authors.forename: Guy E H M
authors.initials: GE
authors.lastname: Rutten
mesh_terms: D020909:Acarbose / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005194:Family Practice / Q000379:methods*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D013810:Therapeutic Equivalency; D014044:Tolbutamide / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D007004:Hypoglycemic Agents; D014044:Tolbutamide; D020909:Acarbose